Zhihua Sun

Dr. Zhihua Sun

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
XWXiaofeng Wang
Xiaofeng Wang
QLQingqing Liu
Qingqing Liu
YFYuanfeng Fu
Yuanfeng Fu
RDRenbo Ding
Renbo Ding
XQXingzhu Qi
Xingzhu Qi
JBJiaolin Bao
Jiaolin Bao
Cancer is a serious disease with high mortality and morbidity worldwide. Natural products have served as a major source for developing new anticancer drugs during recent decades. Magnolol, a representative natural phenolic lignan isolated from Magnolia officinali, has attracted considerable attention for its anticancer properties in recent years. Accumulating preclinical studies have demonstrated the tremendous therapeutic potential of magnolol via a wide range of pharmacological mechanisms against cancer. In this review, we summarized the latest advances in preclinical studies investigating anticancer properties of magnolol and described the important signaling pathways explaining its underlying mechanisms. Magnolol was capable of inhibiting cancer growth and metastasis against various cancer types. Magnolol exerted anticancer effects through inhibiting proliferation, inducing cell cycle arrest, provoking apoptosis, restraining migration and invasion, and suppressing angiogenesis. Multiple signaling pathways were also involved in the pharmacological actions of magnolol against cancer, such as PI3K/Akt/mTOR signaling, MAPK signaling and NF-κB signaling. Based on this existing evidence summarized in the review, we have conclusively confirmed magnolol had a multi-target anticancer effect against heterogeneous cancer disease. It is promising to develop magnolol as a drug candidate for cancer therapy in the future.

7 April 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ZSZhihua Sun
Zhihua Sun
JBJiaolin Bao
Jiaolin Bao
MZManqi Zhangsun
Manqi Zhangsun
Shuai DongShuai Dong
Shuai Dong
DZDongting Zhangsun
Dongting Zhangsun
Sulan LuoSulan Luo
Sulan Luo
The α9-containing nicotinic acetylcholine receptor (nAChR) is increasingly emerging as a new tumor target owing to its high expression specificity in breast cancer. αO-Conotoxin GeXIVA is a potent antagonist of α9α10 nAChR. Nevertheless, the anti-tumor effect of GeXIVA on breast cancer cells remains unclear. Cell Counting Kit-8 assay was used to study the cell viability of breast cancer MDA-MD-157 cells and human normal breast epithelial cells, which were exposed to different doses of GeXIVA. Flow cytometry was adopted to detect the cell cycle arrest and apoptosis of GeXIVA in breast cancer cells. Migration ability was analyzed by wound healing assay. Western blot (WB), quantitative real-time PCR (QRT-PCR) and flow cytometry were used to determine expression of α9-nAChR. Stable MDA-MB-157 breast cancer cell line, with the α9-nAChR subunit knocked out (KO), was established using the CRISPR/Cas9 technique. GeXIVA was able to significantly inhibit the proliferation and promote apoptosis of breast cancer MDA-MB-157 cells. Furthermore, the proliferation of breast cancer MDA-MB-157 cells was inhibited by GeXIVA, which caused cell cycle arrest through downregulating α9-nAChR. GeXIVA could suppress MDA-MB-157 cell migration as well. This demonstrates that GeXIVA induced a downregulation of α9-nAChR expression, and the growth of MDA-MB-157 α9-nAChR KO cell line was inhibited as well, due to α9-nAChR deletion. GeXIVA inhibits the growth of breast cancer cell MDA-MB-157 cells in vitro and may occur in a mechanism abolishing α9-nAChR.

17 January 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
ZSZhihua Sun
Zhihua Sun
MZManqi Zhangsun
Manqi Zhangsun
Shuai DongShuai Dong
Shuai Dong
YLYiqiao Liu
Yiqiao Liu
JQJiang Qian
Jiang Qian
Sulan LuoSulan Luo
Sulan Luo
Nicotinic acetylcholine receptors (nAChRs) are membrane receptors and play a major role in tumorigenesis and cancer progression. Here, we have investigated the differential expression of nAChR subunits in human breast cancer cell lines and breast epithelial cell lines at mRNA and protein levels and the effects of the αO-conotoxin GeXIVA, antagonist of α9α10 nAChR, on human breast cancer cells. Reverse transcription polymerase chain reaction (PCR) demonstrated that all nAChR subunits, except α6, were expressed in the 20 tested cell lines. Real time quantitative PCR (QRT-PCR) suggested that the mRNA of α5, α7, α9 and β4 nAChR subunits were overexpressed in all the breast cancer cell lines compared with the normal epithelial cell line HS578BST. α9 nAChR was highly expressed in almost all the breast cancer cell lines in comparison to normal cells. The different expression is prominent (p < 0.001) as determined by flow cytometry and Western blotting, except for MDA-MB-453 and HCC1395 cell lines. αO-conotoxin GeXIVA that targeted α9α10 nAChR were able to significantly inhibit breast cancer cell proliferation in vitro and merits further investigation as potential agents for targeted therapy.

28 April 2019 in Marine Drugs
Verified
Journal Article
Open access
PDF file
YLYiqiao Liu
Yiqiao Liu
JQJiang Qian
Jiang Qian
ZSZhihua Sun
Zhihua Sun
DZDongting Zhangsun
Dongting Zhangsun
Sulan LuoSulan Luo
Sulan Luo
Nicotinic acetylcholine receptors (nAChRs) are associated with various cancers, but the relation between nAChRs and cervical cancer remains unclear. Therefore, this study investigated the differential expression of nAChR subunits in human cervical cancer cell lines (SiHa, HeLa, and CaSki) and in normal ectocervical cell lines (Ect1/E6E7) at mRNA and protein levels. Two specific nAChR subtype blockers, αO-conotoxin GeXIVA and α-conotoxin TxID, were then selected to treat different human cervical cancer cell lines with specific nAChR subtype overexpression. The results showed that α3, α9, α10, and β4 nAChR subunits were overexpressed in SiHa cells compared with that in normal cells. α9 and α10 nAChR subunits were overexpressed in CaSki cells. α*-conotoxins that targeted either α9α10 or α3β4 nAChR were able to significantly inhibit cervical cancer cell proliferation. These findings may provide a basis for new targets for cervical cancer targeted therapy.

11 December 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SWShuo Wei
Shuo Wei
YWYuefeng Wu
Yuefeng Wu
HHHaihong Hao
Haihong Hao
YLYitao Li
Yitao Li
HLHuili Lu
Huili Lu
HZHui Zhang
Hui Zhang
Multidrug-resistant Staphylococcus aureus (MDR-SA) poses a critical challenge in both clinical and livestock settings, where conventional antibiotics are increasingly ineffective. To explore alternative strategies, we screened 223 compounds and identified ziyuglycoside II as a promising candidate. Its antibacterial and synergistic effects were evaluated using minimum inhibitory concentration (MIC) and checkerboard assays, biofilm inhibition and clearance tests, and mechanistic analyses of membrane integrity, reactive oxygen species (ROS) generation, membrane potential, and ATP synthesis. Biosafety was assessed through hemolysis and mammalian cytotoxicity assays, and therapeutic potential was examined in Galleria mellonella and mouse endometritis models. Ziyuglycoside II exhibited moderate activity (MIC =32 µg/mL) but showed strong synergy with tetracycline (fractional inhibitory concentration index 0.25-0.375), effectively suppressing resistant and susceptible strains. Time-kill assays revealed a reduction of up to 5 log₁₀ in bacterial counts with the combination. The pairing also inhibited biofilm formation, eradicated mature biofilms, and produced markedly thinner, fragmented biofilm structures under confocal microscopy. Mechanistic studies have demonstrated that ziyuglycoside II potentiates tetracycline by disrupting membrane integrity, inducing ROS accumulation, depolarizing the membrane potential, and impairing ATP synthesis. Importantly, no hemolytic or cytotoxic effects were observed at active concentrations. In vivo, the combination outperformed monotherapy by improving host survival, reducing uterine bacterial burden, and alleviating inflammatory responses. Together, these findings establish ziyuglycoside II as a safe and effective tetracycline potentiator, providing a promising strategy to combat MDR S. aureus infections.

16 June 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
MYMeng-Yang Yan
Meng-Yang Yan
CZCai-Hong Zhao
Cai-Hong Zhao
JWJie Wu
Jie Wu
Mohammad AdilMohammad Adil
Mohammad Adil
YLYi-Tao Li
Yi-Tao Li
ZSZhihua Sun
Zhihua Sun
Ceftiofur sodium (CFS) is a clinically significant cephalosporin widely used in the livestock and poultry industries. However, CFS that is not absorbed by animals is excreted in feces, entering the environment and contributing to the emergence of antibiotic-resistant bacteria (ARB) and antibiotic-resistant genes (ARGs). This situation poses substantial challenges to both environmental integrity and public health. Currently, research on the biodegradation of CFS is limited. In this study, we isolated a strain of Escherichia coli, designated E. coli CS-1, a Gram-negative, rod-shaped bacterium capable of utilizing CFS as its sole carbon source, from fecal samples collected from hog farms. We investigated the effects of initial CFS concentration, pH, temperature, and inoculum size on the degradation of CFS by E. coli CS-1 through a series of single-factor experiments conducted under aerobic conditions. The results indicated that E. coli CS-1 achieved the highest CFS degradation rate under the following optimal conditions: an initial CFS concentration of 50 mg/L, a pH of 7.0, a temperature of 37 °C, and an inoculum size of 6% (volume fraction). Under these conditions, E. coli CS-1 was able to completely degrade CFS within 60 h. Additionally, E. coli CS-1 exhibited significant capabilities for CFS degradation. In this study, six major degradation products of (CFS) were identified by UPLC–MS/MS: desfuroyl ceftiofur, 5-hydroxymethyl-2-furaldehyde, 7-aminodesacetoxycephalosporanic acid, 5-hydroxy-2-furoic acid, 2-furoic acid, and CEF-aldehyde. Based on these findings, two degradation pathways are proposed. Pathway I: CFS is hydrolyzed to break the sulfur–carbon (S–C) bond, generating two products. These products undergo subsequent hydrolysis and redox reactions for gradual transformation. Pathway II: The β-lactam bond of CFS is enzymatically cleaved, forming CEF-aldehyde as the primary degradation product, which is consistent with the biodegradation mechanism of most β-lactam antibiotics via β-lactam ring cleavage. Transcriptome sequencing revealed that 758 genes essential for degradation were upregulated in response to the hydrolysis and redox processes associated with CFS. Furthermore, the differentially expressed genes (DEGs) of E. coli CS-1 were functionally annotated using a combination of genomics and bioinformatics approaches. This study highlights the potential of E. coli CS-1 to degrade CFS in the environment and proposes hypotheses regarding the possible biodegradation mechanisms of CFS for future research.